[123I]metaiodobenzylguanidine and [111In]octreotide uptake in benign and malignant pheochromocytomas

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 2, 2001, Pages 685-693

  Van Der Harst, Erwin ^a   De Herder, Wouter W ^a   Bruining, Hajo A ^a   Bonjer, H Jaap ^a   De Krijger, Ronald R ^a   Lamberts, Steven W J ^a   Van De Meiracker, Anton H ^a   Boomsma, Frans ^a   Stijnen, Theo ^a   Krenning, Eric P ^a   Bosman, Fred T ^b   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENALIN; CATECHOLAMINE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CATECHOLAMINE RELEASE; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SCINTIGRAPHY; TUMOR LOCALIZATION; TUMOR VOLUME;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; DISEASE-FREE SURVIVAL; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; NEOPLASM METASTASIS; OCTREOTIDE; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 0037896855     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.2.685     Document Type: Article

References (65)

1. Current management of pheochromocytoma
2. Pheochromocytoma: Current status and changing trends
3. Pheochromocytoma: Operative strategy
4. Effectiveness and limits of pre-operative imaging studies for the localisation of pheochromocytomas and paragangliomas: A review of 282 cases
5. Results of adrenalectomy with various surgical approaches in the treatment of different diseases of the adrenal glands
6. Early experience with laparoscopic approach for adrenalectomy
7. Comparison of three techniques for adrenalectomy
8. Endoscopic retroperitoneal adrenalectomy
9. Retroperitoneal adrenalectomy: Open or endoscopic?
10. Identification of the von Hippel-Lindau disease tumor suppressor gene
11. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
12. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
13. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent
14. The concentration of radioactivity from labeled epinephrine and its precursors in the dog adrenal medulla
15. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison
16. Pheochromocytoma and the normal adrenal medulla: Improved visualization with I-123 MIBG scintigraphy
17. 123I-metaiodobenzylguanidine and x-ray computed tomography: A comparative study
18. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma
19. Octreotide scintigraphy for the detection of paragangliomas
20. Somatostatin receptor scintigraphy
21. Determination of catecholamines in human plasma by high performance liquid chromatography: Comparison between a new method with fluorescence detection and an established method with electrochemical detection
22. Congenital hemihypertrophy and malignant giant pheochromocytoma: A previously undescribed coincidence
23. Scintigraphic localization of pheochromocytoma
24. Human absorbed dose calculations for iodine 131 and iodine 123-labeled metaiodobenzylguanidine (MIBG): A potential myocardial and adrenal medulla imaging agent
25. 131I metaiodobenzylguanidine: Concise communication
26. Questionability of the benefits of routine laparotomy as the surgical approach for pheochromocytomas and abdominal paragangliomas
27. MR imaging and MIBG scintigraphy of pheochromocytomas and extraadrenal functioning paragangliomas
28. 131Iodobenzylguanidine
29. MIBG and radiolabeled octreotide in neuroendocrine tumors
30. Effect of uptake one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine
31. 131I MIBG uptake in phaeochromocytoma and paraganglioma
32. 131 metaiodobenzylguanidine for the localization of suspected pheochromocytoma. Experience in 400 cases
33. 131I]MIBG scintigraphy in the evaluation of suspected pheochromocytoma
34. 131I]MIBG scintigraphy in the diagnosis of pheochromocytoma
35. 131I]-etaiodobenzylguanidine scintigraphy
36. Nuclear medicine imaging of pheochromocytoma and neuroblastoma
37. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neoplasia
38. Adrenal medullary disease in multiple endocrine neoplasia, type 2
39. Adrenal medullary hyperplasia. Hyperplasia-pheochromocytoma sequence
40. Pheochromocytoma due to unilateral adrenal medullary hyperplasia
41. 131I]MIBG scintigraphy in locating pheochromocytomas
42. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes
43. 131I-metaiodobenzylguanidine
44. Malignant phaeochromocytoma: Clinical, biochemical and scintigraphic characterization
45. The diagnosis of nonfunctioning pheochromocytoma. The role of I-123 MIBG imaging
46. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors
47. Pheochromocytomas: Tendency to degenerate and cause paroxysmal hypertension
48. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors
49. 111In-labelled somatostatin analogues for tumor scintigraphy and radionuclide therapy
50. Radiolabeled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
51. Extra-adrenal pheochromocytoma
52. Features of malignancy in a benign pheochromocytoma
53. Bone metastases in pheochromocytoma: Comparative studies of efficacy of imaging
54. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma
55. Detection of malignant pheochromocytoma tumor sites by 111-In-octreotide scintigraphy
56. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma
57. The role of radiolabeled somatostatin analogs in adrenal imaging
58. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 MIBG scintimaging in neural crest tumors
59. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors
60. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extra-adrenal, and malignant pheochromocytomas
61. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors
62. Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: A placebo-controlled trial
63. Yttrium-90 DOTATOC: First clinical results
64. Yttrium-90-labelled somatostatin-analogue for cancer treatment
65. Update on basic research and clinical experience with metaiodobenzylguanidine